NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.14 +0.06 (+0.60 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$10.14
Today's Range$9.91 - $10.36
52-Week Range$5.42 - $20.73
Volume190,409 shs
Average Volume227,873 shs
Market Capitalization$137.51 million
P/E Ratio-4.09
Dividend YieldN/A
Beta4.87

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Debt-to-Equity RatioN/A
Current Ratio6.51
Quick Ratio6.51

Price-To-Earnings

Trailing P/E Ratio-4.09
Forward P/E Ratio-3.39
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales13,749.84
Cash FlowN/A
Price / CashN/A
Book Value$3.71 per share
Price / Book2.73

Profitability

EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-59.98%
Return on Assets-52.73%

Miscellaneous

Employees22
Outstanding Shares13,560,000

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.23. View Zynerba Pharmaceuticals' Earnings History.

What price target have analysts set for ZYNE?

11 brokers have issued 12-month price targets for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $18.45 in the next year. View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
  • 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 60)
  • Ms. Terri B. Sebree, Pres (Age 60)
  • Mr. James E. Fickenscher, CFO & VP of Corp. Devel. (Age 54)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
  • Ms. Suzanne M. Hanlon, Sec., VP of HR & Gen. Counsel (Age 61)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

News headlines about ZYNE stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 0.13 on Accern's scale. They also assigned news coverage about the company an impact score of 43.79 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.27%), Northern Trust Corp (1.23%), Millennium Management LLC (0.77%), A.R.T. Advisors LLC (0.64%), Wells Fargo & Company MN (0.31%) and Alps Advisors Inc. (0.27%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Northern Trust Corp, A.R.T. Advisors LLC, Alps Advisors Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $10.14.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $137.51 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Zynerba Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.45, suggesting that the stock has a possible upside of 81.95%. The high price target for ZYNE is $32.00 and the low price target for ZYNE is $7.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.642.642.642.44
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.45$18.45$18.15$15.1250
Price Target Upside: 81.95% upside74.22% upside50.12% upside12.54% upside

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Consensus Price Target History

Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Cantor FitzgeraldSet Price TargetBuy$20.00MediumView Rating Details
5/8/2018OppenheimerReiterated RatingHoldLowView Rating Details
4/16/2018HC WainwrightSet Price TargetBuy$23.00MediumView Rating Details
3/13/2018Seaport Global SecuritiesReiterated RatingBuyLowView Rating Details
1/29/2018Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$25.50HighView Rating Details
12/4/2017Canaccord GenuitySet Price TargetOutperform ➝ Buy$15.00 ➝ $18.00HighView Rating Details
11/14/2017Piper Jaffray CompaniesBoost Price Target$16.00 ➝ $20.00N/AView Rating Details
10/1/2017Roth CapitalSet Price TargetBuy$15.00MediumView Rating Details
8/15/2017CIBCReiterated RatingOutperform ➝ Market PerformLowView Rating Details
8/15/2017Jefferies GroupDowngradeBuy ➝ Hold$12.00 ➝ $7.00LowView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings History and Estimates Chart

Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.65)($0.62)($0.63)
Q2 20183($0.84)($0.70)($0.76)
Q3 20183($0.81)($0.71)($0.76)
Q4 20183($0.85)($0.70)($0.76)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.6770)($0.91)ViewN/AView Earnings Details
3/12/2018Q4 2017($0.60)($0.60)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.5850)($0.6340)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.5460)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.5250)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
8/27/2015Q2 2015($0.80)$0.02 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.67%
Institutional Ownership Percentage: 21.84%
Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2018Michael RappMajor ShareholderBuy15,000$10.46$156,900.00View SEC Filing  
3/22/2018Michael RappMajor ShareholderBuy10,000$9.28$92,800.00View SEC Filing  
1/2/2018Michael RappMajor ShareholderBuy15,000$12.99$194,850.00View SEC Filing  
10/23/2017Michael RappMajor ShareholderBuy25,745$9.94$255,905.30View SEC Filing  
10/19/2017Michael RappMajor ShareholderBuy44,255$9.59$424,405.45View SEC Filing  
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00336,012View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.0012,200View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.001,354,115View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.003,000View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.0039,893View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines

Source:
DateHeadline
Zynerba Pharmaceuticals Inc (ZYNE) Given Consensus Rating of "Buy" by BrokeragesZynerba Pharmaceuticals Inc (ZYNE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 1:47 PM
Zynerba Pharmaceuticals Inc (ZYNE) Forecasted to Post FY2018 Earnings of ($2.95) Per ShareZynerba Pharmaceuticals Inc (ZYNE) Forecasted to Post FY2018 Earnings of ($2.95) Per Share
www.americanbankingnews.com - May 24 at 8:12 AM
Seaport Global Securities Analysts Cut Earnings Estimates for Zynerba Pharmaceuticals (ZYNE)Seaport Global Securities Analysts Cut Earnings Estimates for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - May 17 at 5:55 AM
Zynerba: Transdermal Cannabinoids Have Significant PotentialZynerba: Transdermal Cannabinoids Have Significant Potential
seekingalpha.com - May 15 at 8:43 AM
 Brokerages Expect Zynerba Pharmaceuticals (ZYNE) to Announce -$0.68 Earnings Per Share Brokerages Expect Zynerba Pharmaceuticals (ZYNE) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - May 14 at 1:18 PM
Zynerba Pharmaceuticals (ZYNE) Upgraded at ValuEngineZynerba Pharmaceuticals (ZYNE) Upgraded at ValuEngine
www.americanbankingnews.com - May 14 at 10:46 AM
The Canadian Cannabis Boom is Heating UpThe Canadian Cannabis Boom is Heating Up
www.prnewswire.com - May 14 at 8:41 AM
Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed RecentlyInterested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently
finance.yahoo.com - May 11 at 5:45 PM
Jefferies Group Analysts Lower Earnings Estimates for Zynerba Pharmaceuticals (ZYNE)Jefferies Group Analysts Lower Earnings Estimates for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - May 11 at 8:16 AM
Analysts Offer Predictions for Zynerba Pharmaceuticals Q2 2018 Earnings (ZYNE)Analysts Offer Predictions for Zynerba Pharmaceuticals' Q2 2018 Earnings (ZYNE)
www.americanbankingnews.com - May 11 at 8:15 AM
Cantor Fitzgerald Reiterates "$20.00" Price Target for Zynerba Pharmaceuticals (ZYNE)Cantor Fitzgerald Reiterates "$20.00" Price Target for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - May 10 at 7:05 PM
Zynerba Pharmaceuticals (ZYNE) Posts Quarterly  Earnings Results, Misses Estimates By $0.23 EPSZynerba Pharmaceuticals (ZYNE) Posts Quarterly Earnings Results, Misses Estimates By $0.23 EPS
www.americanbankingnews.com - May 9 at 1:58 PM
ValuEngine Downgrades Zynerba Pharmaceuticals (ZYNE) to SellValuEngine Downgrades Zynerba Pharmaceuticals (ZYNE) to Sell
www.americanbankingnews.com - May 8 at 11:26 PM
Zynerba Pharmaceuticals (ZYNE) Hold Rating Reaffirmed at OppenheimerZynerba Pharmaceuticals' (ZYNE) Hold Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - May 8 at 3:28 PM
Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
finance.yahoo.com - May 8 at 8:27 AM
Zynerba: 1Q Earnings SnapshotZynerba: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:27 AM
Legal and Medical Cannabis Markets are Outpacing Previous EstimatesLegal and Medical Cannabis Markets are Outpacing Previous Estimates
www.prnewswire.com - May 3 at 5:16 PM
Michael Rapp Purchases 15,000 Shares of Zynerba Pharmaceuticals (ZYNE) StockMichael Rapp Purchases 15,000 Shares of Zynerba Pharmaceuticals (ZYNE) Stock
www.americanbankingnews.com - May 2 at 7:58 PM
Zynerba Pharmaceuticals (ZYNE) Rating Increased to Hold at ValuEngineZynerba Pharmaceuticals (ZYNE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 1:47 PM
Zynerba Pharmaceuticals (ZYNE) Receives Consensus Rating of "Buy" from AnalystsZynerba Pharmaceuticals (ZYNE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 29 at 1:36 PM
Zynerba Pharmaceuticals (ZYNE) Expected to Announce Earnings of -$0.64 Per ShareZynerba Pharmaceuticals (ZYNE) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 27 at 1:29 AM
Cantor Fitzgerald Analysts Give Zynerba Pharmaceuticals (ZYNE) a $20.00 Price TargetCantor Fitzgerald Analysts Give Zynerba Pharmaceuticals (ZYNE) a $20.00 Price Target
www.americanbankingnews.com - April 26 at 8:00 AM
Zynerba Pharma (ZYNE) Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at AANZynerba Pharma (ZYNE) Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at AAN
www.streetinsider.com - April 25 at 5:22 PM
Zynerbas ZYN002 show positive effect in focal seizure extension studyZynerba's ZYN002 show positive effect in focal seizure extension study
seekingalpha.com - April 25 at 8:29 AM
BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 StudyBRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study
www.reuters.com - April 25 at 8:29 AM
Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
finance.yahoo.com - April 25 at 8:29 AM
Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
feeds.benzinga.com - April 23 at 7:30 AM
What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?
finance.yahoo.com - April 22 at 6:26 PM
Maxim Group Analysts Give Zynerba Pharmaceuticals (ZYNE) a $32.00 Price TargetMaxim Group Analysts Give Zynerba Pharmaceuticals (ZYNE) a $32.00 Price Target
www.americanbankingnews.com - April 20 at 1:54 PM
HC Wainwright Reiterates "$23.00" Price Target for Zynerba Pharmaceuticals (ZYNE)HC Wainwright Reiterates "$23.00" Price Target for Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - April 16 at 8:17 AM
Zynerba Pharmaceuticals Appoints John P. Butler to Board of DirectorsZynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
feeds.benzinga.com - April 16 at 7:46 AM
Can Cannabis Treat Seizures? Biotechs Say The Answer Is YesCan Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
finance.yahoo.com - April 13 at 5:23 PM
HC Wainwright Lowers Zynerba Pharmaceuticals (ZYNE) to NeutralHC Wainwright Lowers Zynerba Pharmaceuticals (ZYNE) to Neutral
www.americanbankingnews.com - April 12 at 9:00 PM
Zynerba Pharmaceuticals initiates Phase 2 trial of ZYN002 in DEEZynerba Pharmaceuticals initiates Phase 2 trial of ZYN002 in DEE
seekingalpha.com - April 10 at 5:22 PM
Oppenheimer Downgrades Zynerba Pharmaceuticals (ZYNE) to Market PerformOppenheimer Downgrades Zynerba Pharmaceuticals (ZYNE) to Market Perform
www.americanbankingnews.com - April 10 at 11:28 AM
BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)
www.reuters.com - April 10 at 8:40 AM
Zynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic EncephalopathiesZynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
www.streetinsider.com - April 10 at 8:40 AM
Zacks: Brokerages Anticipate Zynerba Pharmaceuticals (ZYNE) Will Post Earnings of -$0.64 Per ShareZacks: Brokerages Anticipate Zynerba Pharmaceuticals (ZYNE) Will Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 10 at 3:13 AM
Zynerba Pharmaceuticals (ZYNE) Stock Rating Upgraded by Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) Stock Rating Upgraded by Cantor Fitzgerald
www.americanbankingnews.com - April 8 at 3:17 PM
Zynerba Pharmaceuticals (ZYNE) Given Consensus Recommendation of "Buy" by BrokeragesZynerba Pharmaceuticals (ZYNE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 1:47 PM
Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
finance.yahoo.com - April 3 at 5:25 PM
Zynerba Pharmaceuticals (ZYNE) Cut to "Strong Sell" at ValuEngineZynerba Pharmaceuticals (ZYNE) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Zynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 5:08 PM
Zynerba Pharmaceuticals (ZYNE) Given Hold Rating at OppenheimerZynerba Pharmaceuticals (ZYNE) Given Hold Rating at Oppenheimer
www.americanbankingnews.com - March 30 at 5:08 PM
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating ...Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating ...
globenewswire.com - March 28 at 8:40 AM
Zynerba Pharma (ZYNE) Announces Publication of Preclinical Data in NeuropsychopharmacologyZynerba Pharma (ZYNE) Announces Publication of Preclinical Data in Neuropsychopharmacology
www.streetinsider.com - March 26 at 5:09 PM
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction ModelZynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
finance.yahoo.com - March 26 at 8:33 AM
 Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.65 EPS Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.65 EPS
www.americanbankingnews.com - March 24 at 1:12 AM
Insider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Buys 10,000 Shares of StockInsider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Buys 10,000 Shares of Stock
www.americanbankingnews.com - March 23 at 10:35 AM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of ... - GlobeNewswire (press release)Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:31 AM

SEC Filings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zynerba Pharmaceuticals (NASDAQ ZYNE) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.